Targeted Antigens of CAR-T Cell Therapy Information
| Target General Information | |||||
|---|---|---|---|---|---|
| Target ID | T37539 | Target Info | |||
| Target Name | B-cell receptor CD22 (CD22) | ||||
| Synonyms | T-cell surface antigen Leu-14; Siglec-2; Sialic acid-binding Ig-like lectin 2; SIGLEC2; Leu-14; BL-CAM; B-lymphocyte cell adhesion molecule | ||||
| Target Type | Successful Target | ||||
| Gene Name | CD22 | ||||
| Biochemical Class | Immunoglobulin | ||||
| UniProt ID | |||||
| Targeted Antigens of CAR-T Cell Therapy | |||||
| CAR T-Cell Therapy Drug(s) | CAR-T cells targeting CD22 | Drug Info | Phase 2 | Non-hodgkin lymphoma | [1] |
| 4SCAR19 and 4SCAR22 | Drug Info | Phase 1/2 | B-cell lymphoma | [2] | |
| 4SCAR19/22 T cells | Drug Info | Phase 1/2 | leukaemia | [3] | |
| Anti-CD19/22-CAR vector-transduced T cells | Drug Info | Phase 1/2 | Prolymphocytic leukaemia | [4] | |
| Anti-CD22 CAR-T cells | Drug Info | Phase 1/2 | Lymphoma | [5] | |
| Anti-CD22-CAR-transduced T cells | Drug Info | Phase 1/2 | Lymphoma | [6] | |
| AUTO3 | Drug Info | Phase 1/2 | Diffuse large B-cell lymphoma | [7], [8] | |
| CAR-T cells targeting CD22 | Drug Info | Phase 1/2 | Multiple myeloma | [9] | |
| CART-19/22 | Drug Info | Phase 1/2 | leukaemia | [10] | |
| CD19 and CD22 CAR-T Cells | Drug Info | Phase 1/2 | leukaemia | [11] | |
| CD19 and CD22 CAR-T Cells | Drug Info | Phase 1/2 | Lymphoma | [12] | |
| CD19-TCRz-41BB and CD22-TCRz-41BB CAR-T Cells | Drug Info | Phase 1/2 | Haematopoietic/lymphoid cancer | [13] | |
| CD22 CAR-T | Drug Info | Phase 1/2 | B-cell lymphoma | [14] | |
| CD22-Targeted CAR-T cells | Drug Info | Phase 1/2 | Lymphoma | [15] | |
| Anti-CD22 CAR-T cells | Drug Info | Phase 1 | Lymphoma | [16] | |
| CART-22 cells | Drug Info | Phase 1 | Acute lymphoblastic leukaemia | [17] | |
| CART22 cells | Drug Info | Phase 1 | Acute lymphoblastic leukaemia | [18] | |
| CART22 cells expressing anti-CD22 scFv TCRz:41BB | Drug Info | Phase 1 | Acute lymphoblastic leukaemia | [19] | |
| CART22-65s cells | Drug Info | Phase 1 | Acute lymphoblastic leukaemia | [20] | |
| CART22-65s cells and huCART19 Cells | Drug Info | Phase 1 | Acute lymphoblastic leukaemia | [20] | |
| CD19/CD22 CAR T cells | Drug Info | Phase 1 | Acute lymphoblastic leukaemia | [21] | |
| CD19/CD22 CAR T-Cells | Drug Info | Phase 1 | Non-hodgkin lymphoma | [22] | |
| CD19/CD22 Chimeric Antigen Receptor T Cells | Drug Info | Phase 1 | Mediastinal large B-cell lymphoma | [23] | |
| CD22-CART | Drug Info | Phase 1 | leukaemia | [24] | |
| CD22-specific CAR T-cells also expressing an EGFRt | Drug Info | Phase 1 | leukaemia | [25] | |
| Donor-derived CD19/22 bispecific CAR-T cells | Drug Info | Phase 1 | leukaemia | [26] | |
| Dual Specificity CD19 and CD22 CAR-T Cell | Drug Info | Phase 1 | Lymphoma | [27] | |
| Patient-derived CD19- and CD22 specific CAR | Drug Info | Phase 1 | Lymphoma | [28] | |
| Retroviral vector-transduced autologous T cells to express CD22-specific CARs | Drug Info | Phase 1 | Mantle cell lymphoma | [29] | |
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT03196830) CAR-T for R/R B-NHL | ||||
| REF 2 | ClinicalTrials.gov (NCT03125577) Combination CAR-T Cell Therapy Targeting Hematological Malignancies | ||||
| REF 3 | ClinicalTrials.gov (NCT03098355) Interleukin-2 Following 4SCAR19/22 T Cells Targeting Refractory and/or Recurrent B Cell Malignancies | ||||
| REF 4 | ClinicalTrials.gov (NCT03185494) Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD22 | ||||
| REF 5 | ClinicalTrials.gov (NCT03638206) Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies | ||||
| REF 6 | ClinicalTrials.gov (NCT03262298) Anti-CD22 CAR-T Cell Therapy Targeting B Cell Malignancies | ||||
| REF 7 | ClinicalTrials.gov (NCT03289455) CD19 /22 CAR T Cells (AUTO3) for the Treatment of B Cell ALL | ||||
| REF 8 | ClinicalTrials.gov (NCT03287817) CD19/22 CAR T Cells (AUTO3) for the Treatment of Diffuse Large B Cell Lymphoma | ||||
| REF 9 | ClinicalTrials.gov (NCT03312205) CAR-T Cells for Relapsed or Refractory Haematopoietic and Lymphoid Malignancies | ||||
| REF 10 | ClinicalTrials.gov (NCT03614858) CD19/CD22-targeted Chimeric Antigen Receptor Engineered T Cell (CART) in B-Cell Acute Lymphoblastic Leukemia. | ||||
| REF 11 | ClinicalTrials.gov (NCT03398967) A Feasibility and Safety Study of Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cell Immunotherapy for Relapsed or Refractory Leukemia and Lymphoma | ||||
| REF 12 | ClinicalTrials.gov (NCT03468153) Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Relapsed and Refractory Lymphoma | ||||
| REF 13 | ClinicalTrials.gov (NCT02903810) Combination Transfer of CD19-TCRz-41BB and CD22-TCRz-41BB CAR-T Cells for B-cell Hematologic Malignancy | ||||
| REF 14 | ClinicalTrials.gov (NCT02794961) CD22 Targeting CAR-T Therapy Against B Cell Hematological Malignancies | ||||
| REF 15 | ClinicalTrials.gov (NCT02935153) A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies | ||||
| REF 16 | ClinicalTrials.gov (NCT03121625) CAR-T Therapy in Relapsed or Refractory Haematopoietic and Lymphoid Malignancies | ||||
| REF 17 | ClinicalTrials.gov (NCT03291444) CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS | ||||
| REF 18 | ClinicalTrials.gov (NCT02588456) Pilot Study of Autologous Anti-CD22 Chimeric Antigen Receptor Redirected T Cells In Patients With Chemotherapy Resistant Or Refractory Acute Lymphoblastic Leukemia | ||||
| REF 19 | ClinicalTrials.gov (NCT02650414) CD22 Redirected Autologous T Cells for ALL | ||||
| REF 20 | ClinicalTrials.gov (NCT03620058) CART22 Alone or in Combination With huCART19 for ALL | ||||
| REF 21 | ClinicalTrials.gov (NCT03241940) CD19/CD22 Chimeric Antigen Receptor T Cells and Chemotherapy in Treating Children or Young Adults With Recurrent or Refractory CD19 Positive B Acute Lymphoblastic Leukemia | ||||
| REF 22 | ClinicalTrials.gov (NCT03448393) CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies | ||||
| REF 23 | ClinicalTrials.gov (NCT03233854) CD19/CD22 Chimeric Antigen Receptor T Cells and Chemotherapy in Treating Patients With Recurrent or Refractory CD19 Positive Diffuse Large B-Cell Lymphoma or B Acute Lymphoblastic Leukemia | ||||
| REF 24 | ClinicalTrials.gov (NCT03407859) Sequential Treatment With CD20/CD22/CD10-CART After CD19-CART Treatment Base on MRD in Relapsed/Refractory B-ALL | ||||
| REF 25 | ClinicalTrials.gov (NCT03244306) A Phase 1 Study of CD22-CAR TCell Immunotherapy for CD22+ Leukemia and Lymphoma | ||||
| REF 26 | ClinicalTrials.gov (NCT03463928) A Feasibility and Safety Study of Concomitant Therapy With Allo-CAR-T Cells and Allo-HSCT in Patients With Relapse or Refractory Leukemia | ||||
| REF 27 | ClinicalTrials.gov (NCT03593109) Safety and Efficacy Study of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy in Relapsed or Refractory Lymphoma | ||||
| REF 28 | ClinicalTrials.gov (NCT03330691) A Feasibility and Safety Study of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Leukemia and Lymphoma | ||||
| REF 29 | ClinicalTrials.gov (NCT02721407) Anti-CD22 CAR-T Therapy for CD19-refractory or Resistant Lymphoma Patients | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Wang and Dr. Li.